Tremfya review. Tremfya for Psoriasis: Comprehensive Review of Effectiveness and Side Effects
How effective is Tremfya for treating psoriasis. What are the most common side effects of Tremfya. Who is a good candidate for Tremfya treatment. How does Tremfya compare to other psoriasis medications. What should patients know before starting Tremfya.
Understanding Tremfya: A Breakthrough Treatment for Psoriasis
Tremfya (guselkumab) has emerged as a significant treatment option for individuals suffering from moderate to severe plaque psoriasis. As a biologic medication, it targets specific components of the immune system to reduce inflammation and alleviate psoriasis symptoms. But how effective is it really, and what do patients need to know?
What is Tremfya and How Does it Work?
Tremfya is an injectable medication that belongs to a class of drugs called interleukin-23 (IL-23) inhibitors. It works by blocking IL-23, a protein that plays a crucial role in the inflammatory process associated with psoriasis. By inhibiting this protein, Tremfya helps to reduce the overproduction of skin cells and inflammation, leading to clearer skin for many patients.
Effectiveness of Tremfya: Patient Experiences and Clinical Data
The effectiveness of Tremfya varies among individuals, but many patients report significant improvements in their psoriasis symptoms. Let’s examine some real-world experiences and clinical findings:
- Complete clearance: Several patients reported complete clearance of psoriasis plaques within 8-13 weeks of starting treatment.
- Long-term efficacy: Some users maintained clear skin for up to two years with continued use.
- Improvement in quality of life: Many patients expressed increased confidence and ability to engage in activities they previously avoided due to psoriasis.
- Efficacy in difficult-to-treat areas: Some users noted improvement in scalp psoriasis, which can be particularly challenging to manage.
Clinical trials have shown that a significant percentage of patients achieve clear or almost clear skin with Tremfya treatment. However, individual responses can vary, and some patients may experience less dramatic improvements.
How Quickly Does Tremfya Work?
The onset of action for Tremfya can differ among patients. Some report noticeable improvements within the first few weeks, while others may take longer to see significant changes. Typically, the full effects of Tremfya are observed after several months of consistent treatment.
Side Effects and Safety Considerations of Tremfya
While many patients tolerate Tremfya well, it’s crucial to be aware of potential side effects and safety considerations:
Common Side Effects
- Upper respiratory infections
- Headaches
- Injection site reactions
- Joint pain
- Diarrhea
- Gastroenteritis
Less Common but Serious Side Effects
Some patients have reported more severe side effects, including:
- Severe allergic reactions
- Infections
- Mental health issues (in rare cases)
It’s important to note that while some patients reported mental health symptoms like anxiety and paranoia, these are not listed as common side effects in the official drug information. Always consult with a healthcare provider about any unusual symptoms or concerns.
Comparing Tremfya to Other Psoriasis Treatments
Tremfya is one of several biologic medications available for treating psoriasis. How does it stack up against other options?
Tremfya vs. Stelara
Some patients who switched from Stelara to Tremfya reported improved efficacy, particularly in hard-to-treat areas like the scalp. However, others found Stelara to be more effective or better tolerated. The choice between these medications often depends on individual patient factors and response.
Tremfya vs. Other Biologics
Comparisons with other biologics like Siliq or Humira are less common in patient reviews, but clinical studies have shown Tremfya to be highly effective compared to some older biologic treatments. The choice of biologic often depends on factors such as:
- Individual patient characteristics
- Presence of psoriatic arthritis
- Prior treatment history
- Insurance coverage and cost considerations
Dosing and Administration of Tremfya
Understanding the dosing schedule and administration method of Tremfya is crucial for patients considering or starting this treatment.
How is Tremfya Administered?
Tremfya is administered via subcutaneous injection. The medication comes in a pre-filled syringe or auto-injector pen, allowing for self-administration at home after proper training from a healthcare provider.
What is the Typical Dosing Schedule for Tremfya?
The standard dosing schedule for Tremfya is as follows:
- Initial dose at week 0
- Second dose at week 4
- Subsequent doses every 8 weeks
This schedule may be adjusted based on individual patient response and healthcare provider recommendations.
Cost and Insurance Considerations for Tremfya
The cost of Tremfya can be a significant concern for many patients. Without insurance, the medication can be prohibitively expensive, with some patients reporting costs of over $3,000 per injection.
Insurance Coverage for Tremfya
Many private insurance plans cover Tremfya, often with a reasonable copay. However, coverage can vary significantly between plans and providers. Some patients report difficulties with Medicare coverage, experiencing high out-of-pocket costs.
Patient Assistance Programs
For patients struggling with the cost of Tremfya, the manufacturer offers patient assistance programs that may help reduce out-of-pocket expenses. It’s essential to explore these options and discuss cost concerns with healthcare providers and insurance companies.
Long-Term Outlook and Maintenance with Tremfya
For many patients, Tremfya offers the possibility of long-term psoriasis management with minimal side effects. However, the long-term outlook can vary among individuals.
Maintenance Therapy
Most patients who respond well to Tremfya continue with maintenance therapy, receiving injections every 8 weeks. Some report occasional breakthrough symptoms, particularly in the week or two before their next scheduled dose.
Long-Term Efficacy and Safety
While long-term data is still being collected, many patients report sustained efficacy over several years of treatment. Ongoing monitoring for side effects and regular check-ups with healthcare providers are essential for long-term safety.
Making the Decision: Is Tremfya Right for You?
Deciding whether to start Tremfya treatment is a personal decision that should be made in consultation with a dermatologist or rheumatologist. Factors to consider include:
- Severity and extent of psoriasis
- Previous treatments and their efficacy
- Presence of psoriatic arthritis
- Overall health status and risk factors
- Cost and insurance coverage
- Willingness to commit to long-term injectable therapy
It’s important to have a thorough discussion with your healthcare provider about the potential benefits and risks of Tremfya in your specific case.
Questions to Ask Your Doctor About Tremfya
When considering Tremfya, it’s helpful to prepare a list of questions for your healthcare provider. Some important questions to consider include:
- How does Tremfya compare to other treatment options for my specific case of psoriasis?
- What kind of improvement can I realistically expect with Tremfya?
- How long will it take to see results?
- What are the most common side effects I should watch for?
- How will we monitor the effectiveness and safety of the treatment?
- What should I do if I experience a flare-up while on Tremfya?
- Are there any lifestyle modifications I should make while on this medication?
- How will Tremfya affect my ability to receive vaccines?
- What are my options if Tremfya doesn’t work or stops working?
By engaging in an open and thorough discussion with your healthcare provider, you can make an informed decision about whether Tremfya is the right choice for managing your psoriasis.
Living with Psoriasis: Beyond Medication
While Tremfya and other biologic medications can be highly effective in managing psoriasis, it’s important to remember that treatment extends beyond just taking medication. A holistic approach to psoriasis management often yields the best results.
Lifestyle Modifications for Psoriasis Management
In addition to medication, consider incorporating the following lifestyle modifications to support your psoriasis treatment:
- Stress management: Practice relaxation techniques, meditation, or yoga to reduce stress, which can trigger psoriasis flares.
- Dietary changes: Some patients find that certain dietary modifications, such as reducing inflammatory foods, can help manage their symptoms.
- Moisturizing: Regular use of moisturizers can help reduce dryness and itching associated with psoriasis.
- Sun exposure: Controlled, moderate sun exposure can be beneficial for some psoriasis patients, but always consult with your doctor first.
- Avoiding triggers: Identify and avoid personal triggers that may exacerbate your psoriasis, such as certain foods, alcohol, or environmental factors.
Mental Health and Psoriasis
Living with a chronic condition like psoriasis can take a toll on mental health. It’s important to address these aspects of the disease as well:
- Seek support: Join support groups or online communities for individuals with psoriasis to share experiences and coping strategies.
- Consider therapy: If psoriasis is affecting your mental health, consider talking to a therapist who has experience with chronic health conditions.
- Practice self-care: Engage in activities that boost your self-esteem and overall well-being.
Remember, managing psoriasis is a journey, and finding the right combination of treatments and lifestyle modifications may take time. Stay patient and work closely with your healthcare team to achieve the best possible outcomes.
The Future of Psoriasis Treatment: What’s on the Horizon?
As research in psoriasis treatment continues to advance, new therapies and approaches are constantly being developed. While Tremfya represents a significant step forward in psoriasis management, it’s worth looking at what the future might hold for patients with this condition.
Emerging Therapies and Research
Several areas of research show promise for future psoriasis treatments:
- Targeted therapies: Researchers are working on even more specific targeted therapies that may offer improved efficacy with fewer side effects.
- Combination therapies: Studies are exploring the potential benefits of combining different types of treatments for enhanced efficacy.
- Personalized medicine: Advances in genetic research may lead to more personalized treatment approaches based on individual patient characteristics.
- Topical treatments: New formulations of topical treatments are being developed that may offer improved efficacy for mild to moderate psoriasis.
- Oral medications: Research continues on new oral medications that may provide an alternative to injectable biologics.
The Role of Tremfya in Future Treatment Paradigms
As new treatments emerge, the role of Tremfya and other current biologics may evolve. It’s likely that these medications will continue to play a significant role in psoriasis management, potentially as part of combination therapies or as options for patients who don’t respond to newer treatments.
Staying informed about new developments in psoriasis treatment can help patients and healthcare providers make informed decisions about long-term management strategies. Regular check-ups and open communication with your dermatologist or rheumatologist are key to staying up-to-date on the latest treatment options and determining the best approach for your individual case.
As we continue to learn more about the underlying mechanisms of psoriasis and develop new targeted therapies, the future looks bright for individuals living with this challenging condition. While Tremfya represents a significant advancement in psoriasis treatment, it’s just one step in the ongoing journey towards better management and potential cures for psoriasis.
Effectiveness, Ease of Use, and Satisfaction
Show ratings & reviews for
3.6 Overall Rating
Share Your Experience
Effectiveness
Tooltip icon
See more
Ease of Use
Tooltip icon
See more
Satisfaction
Tooltip icon
See more
Most voted positive review
5 People found this comment helpful
Have Psoriasis plaque on elbows and lower legs for over 20 years. First biological i have tried. Just had third injection so now at 13 week. Completely cleared. Still see slight scaring on my lower legs but fading. No known side effects.
Shared reviews and ratings
SORT BY Condition: Moderate to Severe Plaque Psoriasis
Overall rating 5.0
EffectivenessEase of UseSatisfaction
I have had severe psoriasis for over 40 years. I have tried everything from topicals, pills, injections, sun/uv and nothing helped. I debated for years before trying a biologic but finally wanted to see if I could improve my quality of life.
I started Tremfya in march of 2021, exactly 8 weeks before my first scheduled vacation. To my surprise, I was able to go swimming for the first time in 40 years without embarassment! I have been completely clear for almost 2 years now with an occaisonal reminder spot usually something almost unnoticable which usually pops up generally a week or two before the next injection. It has always cleared quickly following my next injection. I have never been happier! I recently switched insurance providers (Jan 23) and was afraid I may lose coverage, but my doctor was able to get it approved! I could not live like I do today without it! Best decision I ever made!Read More Read Less
1
ShapeCreated with Sketch.thumb_up copy 5Created with Sketch.Report this post
Fill 3Created with Sketch. Condition: Psoriasis associated with Arthritis
Overall rating 5.0
EffectivenessEase of UseSatisfaction
I took tremfya and my joint paint and swelling stopped .
My psoriasis cleared up . This medication has improved my quality of life.
1
ShapeCreated with Sketch.thumb_up copy 5Created with Sketch.Report this post
Fill 3Created with Sketch. Condition: Moderate to Severe Plaque Psoriasis
Overall rating 4.0
EffectivenessEase of UseSatisfaction
I have used Tremfya for four years. It worked fine and I was paying five dollars per shot every two months with my Blue Cross Blue Shield plan. I am now in Medicare and have a very good prescription plan but they want over $3000 per shot every two months. I believe it is a scam to get you hooked on their shot and then charge a ridiculous price
ShapeCreated with Sketch. 1
thumb_up copy 5Created with Sketch.Report this post
Fill 3Created with Sketch. Condition: Moderate to Severe Plaque Psoriasis
Overall rating 2.7
EffectivenessEase of UseSatisfaction
Switched from Siliq to Tremfya due to insurance issues.
.. not by choice. Tremfya by far worst performing injection. Psoriasis spots reappeared on my legs- derm prescribed a topical. Hadn’t used topicals in years. The worst part: upper respiratory infections galore. Four in 2 months with most recent this week resulting in ear infection requiring antibiotics. Head and body aches common with Tremfya as well. Not a good medicine for me at all.
1
ShapeCreated with Sketch.thumb_up copy 5Created with Sketch.Report this post
Fill 3Created with Sketch. Condition: Moderate to Severe Plaque Psoriasis
Overall rating 3.3
EffectivenessEase of UseSatisfaction
2 weeks into my first injection; seeing some very slight improvement. Some plaques have stopped “re-plaquing” , others have not changed. I seem to be itching more than usual though. Scalp plaques are starting to lift which is difficult to deal with. Side effects are very minimal, minor nausea and slight joint pain.
Looking forward to more improvements with the 2nd injection.
1
ShapeCreated with Sketch.thumb_up copy 5Created with Sketch.Report this post
Fill 3Created with Sketch. Condition: Moderate to Severe Plaque Psoriasis
Overall rating 2.3
EffectivenessEase of UseSatisfaction
Substantial mental side effects including paranoia and anxiety. Not a listed side effect, but effects stopped once loading dose cleared my system. Chose not to go for second dose.
3
ShapeCreated with Sketch.thumb_up copy 5Created with Sketch.Report this post
Fill 3Created with Sketch. Condition: Moderate to Severe Plaque Psoriasis
Overall rating 1.0
EffectivenessEase of UseSatisfaction
I was on Stelara for over 7 years and my Dr though Tremfya would help with the area’s in my hair line that have not gone away.
One shot and I was in agony! I developed migraine headache the next day that lasted for over 3 weeks. So this drug is not for me! Back on Stelara next visit.
2
ShapeCreated with Sketch.thumb_up copy 5Created with Sketch.Report this post
Fill 3Created with Sketch. Condition: Moderate to Severe Plaque Psoriasis
Overall rating 2.3
EffectivenessEase of UseSatisfaction
I experienced severe thigh muscle pain during the short 2 months I was on this biologic that stopped as soon as I changed to a different med. I have been on Enbrel, Humira, cosentyx, tremfya then taltz. The muscle pain was intolerable and it hurt to walk.
2
ShapeCreated with Sketch.thumb_up copy 5Created with Sketch.Report this post
Fill 3Created with Sketch. Condition: Other
Overall rating 5.0
EffectivenessEase of UseSatisfaction 2
ShapeCreated with Sketch.
1
thumb_up copy 5Created with Sketch.Report this post
Fill 3Created with Sketch. Condition: Other
Overall rating 5.0
EffectivenessEase of UseSatisfaction
Have Psoriasis plaque on elbows and lower legs for over 20 years. First biological i have tried. Just had third injection so now at 13 week. Completely cleared. Still see slight scaring on my lower legs but fading. No known side effects.
5
ShapeCreated with Sketch. 1
thumb_up copy 5Created with Sketch.Report this post
Fill 3Created with Sketch.
IMPORTANT INFORMATION ABOUT USER-GENERATED CONTENT ON WEBMD
The opinions expressed in WebMD User-generated content areas like communities, reviews, ratings, or blogs are solely those of the User, who may or may not have medical or scientific training. These opinions do not represent the opinions of WebMD. User-generated content areas are not reviewed by a WebMD physician or any member of the WebMD editorial staff for accuracy, balance, objectivity, or any other reason except for compliance with our Terms and Conditions.
Read More
Tremfya® ranks highest for skin clearance for Psoriatic Arthritis patients
news
10
SHARES
Newly published Network Meta-Analysis (NMA) from Janssen indirectly compares all published Phase III data for approved treatments for adults with active Psoriatic Arthritis (PsA).
The Janssen Pharmaceutical Companies of Johnson & Johnson have announced a Network Meta-Analysis (NMA) comparing first-in-class interleukin (IL)-23 inhibitor Tremfya® (guselkumab) to all advanced therapies approved for active psoriatic arthritis (PsA) using data from 33 Phase III randomised clinical trials (RCTs).
The NMA concluded Tremfya ranked highest for skin clearance based on Psoriasis (PsO) Area Severity Index (PASI) 90 response among 23 treatment regimens (15 unique treatments including IL-23 inhibitors like Tremfya and risankizumab, subcutaneous [SC] tumour necrosis factor inhibitors [TNFi], and Janus kinase inhibitors [JAKi]).
In terms of joint inflammation improvement, both Tremfya dosing regimens (100mg every four weeks [q4w] and every eight weeks [q8w]) were comparable to most other treatments for the modified van der Heijde-Sharp (vdH-S) score, and Tremfya was generally comparable to TNFi and most IL-17Ai for American College of Rheumatology (ACR) 20 response.
The analysis also confirmed the established safety profile of Tremfya in active PsA.
The NMA is being presented at the Maui Dermatology 2022 Meeting taking place between 24 – 28 January 2022. Tremfya is US Food and Drug Administration (FDA) approved for administration as a 100mg SC injection q8w, following two initial doses at weeks 0 and 4.
An NMA is a structured, protocol-driven analytical process widely accepted and utilised by regulatory agencies, health technology assessment agencies and medical guideline committees to comparatively evaluate treatment options where head-to-head data are limited or unavailable. NMA is the most cited and the most comprehensive method available to compare studies indirectly; however, NMAs cannot replace, and should not be considered the same as, head-to-head clinical trials.
In this NMA, the timing of primary endpoint assessment varied across RCTs and placebo was used as the reference treatment throughout with the exception of two head-to-head studies.
Baseline risk adjustment was used to account for heterogeneity across study populations.
The NMA builds on previous analyses, including a 2021 publication in Rheumatology, and now incorporates all recent clinical data updates, including the COSMOS study of Tremfya in PsA patients who had an inadequate response to TNFi, as well as data for two new comparators, the IL-23i risankizumab and the JAKi upadacitinib.
NMA results:
- Skin clearance: Tremfya ranked first and second in PASI 90 response for q4w and q8w dosing, respectively
- Joint inflammation improvement: Tremfya was comparable to SC TNFi and most IL-17Ai, as measured by ACR20 response. While dosing frequency impacted modified vdH-S score, both Tremfya dosing regimens achieved improvements that were comparable to most treatments and both ranked more highly on vdH-S score than risankizumab and upadacitinib
- Low numbers of Serious Adverse Events (SAEs): Tremfya showed low rates of SAEs, with both dosing regimens ranking favourably among the 23 treatments for low rates of events.
The number of SAEs for Tremfya were consistent with its established safety profile.
The number of SAEs for Tremfya were consistent with its established safety profile.“Psoriatic arthritis is a complex disease, and physicians must consider many factors when making treatment decisions, including the relative efficacy of therapies in treating both skin and joints, as well as established safety,” stated Dr Terence Rooney, Vice President, Rheumatology and Maternal-Fetal Immunology Disease Area Leader, Janssen Research & Development, LLC. “NMAs are a comprehensive, well-established approach and can provide physicians with useful information on available therapies.”
Tremfya was approved in the US for the treatment of adult patients with moderate to severe plaque PsO in July 2017 and in July 2020 for adults with active PsA. The PsA approval was based on results from DISCOVER-1 and DISCOVER-2, which showed Tremfya achieved the studies’ primary endpoint of ACR20 response at 24 weeks.
Janssen will present five additional posters at the Maui Dermatology Meeting, including the study design of APEX (NCT04882098), investigating the effect of Tremfya on radiographic progression; the design of the SOLSTICE trial (NCT04936308), which further evaluates Tremfya efficacy for PsA patients with intolerance or inadequate response to TNF therapy; evidence of molecular and genetic distinctions between patients with axial PsA (axPsA) and ankylosing spondylitis and the significant pharmacodynamic effects of Tremfya in axPsA patients; and real-world evidence for PsA patients initiating Tremfya treatment in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry.
Related topics
Antibodies, Biologics, Clinical Trials, Drug Development, Drug Safety, Drug Targets, Research & Development (R&D), Therapeutics
27 January 2022
Shares
Related topics
Antibodies, Biologics, Clinical Trials, Drug Development, Drug Safety, Drug Targets, Research & Development (R&D), Therapeutics
Tremfya® (guselcumab) has been included in the list of Vital and Essential Drugs since 2021
Home >
Industry news >
Tremfya® (guselcumab) has been added to the list of Vital and Essential Drugs since 2021
The effectiveness of Tremfya ® is maintained for at least five years in more than 80% of patients 1 which exceeds the capabilities of existing drugs for the treatment of psoriasis 2,3,4 MOSCOW, February 4, 2021 – Janssen, a pharmaceutical division of Johnson & Johnson LLC, announces that Tremfya (guselcumab), a drug intended for the treatment of moderate to severe plaque psoriasis, has been included in the list of essential and essential drugs (VED) from 1 January 2021. Psoriasis is a severe systemic disease that has a serious negative impact primarily on the quality of life of patients 5 . The most common form of psoriasis is plaque psoriasis, usually manifesting as thick, red, or inflamed skin covered in silvery scales called plaques 6 . The undulating nature of the course of the disease leads to the fact that even with the disappearance of plaques, many patients continue to live in fear of their new appearance 7 . Guselcumab ® is a biologic agent of the interleukin 23 inhibitor class for the treatment of moderate to severe plaque psoriasis in adult patients in whom systemic therapy is indicated 8 . Guselcumab is a fully human monoclonal antibody with low immunogenicity and a favorable safety profile. More than 80% of patients achieved and maintained near-complete skin clearance within five years of treatment with Guselcumab 9 . “Inclusion of the drug in the list of Vital and Essential Drugs is an important step for Russian patients with severe and moderate psoriasis, since the use of guselkumab prevents the disability of young, able-bodied and socially active members of society, and also solves an important social problem for patients: it improves the quality of life and contributes to the preservation of working capacity 9,2,10,11,12,13,14,15 “,” comments Katerina Pogodina , Janssen Russia and CIS Managing Director, General Director of Johnson & Johnson LLC. The drug was registered in Russia in August 2019. Guselcumab ® is designed to improve the quality of life of patients with severe forms of psoriasis, helping them to maintain their ability to work and social activity. It is the first biologic that selectively blocks interleukin (IL)-23, a key cytokine in the immune system’s inflammatory response in psoriasis 16,17,18 . “Psoriasis is not just a skin disease, but a systemic disease that affects the state of internal organs and the nervous system as well. Due to the presence of systemic inflammation, the risk of death in such patients from cardiovascular diseases increases by 1.5 times, and the risk of developing myocardial infarction – by 3 times. The life expectancy of patients with psoriasis is on average 5-7 years less than in the general population 19.20.21 . Being one of the most effective drugs registered in Russia against psoriasis 2,6,14 , Guselkumab ® suppresses systemic inflammation, thereby reducing the risk of developing cardiovascular diseases, psoriatic arthritis and subsequent disability, which improves the quality and life expectancy of patients. With the inclusion of Guselkumab in the list of vital and essential drugs, innovative therapy will become available to the largest number of patients who really need it” , – comments Konstantin Igorevich Raznatovsky , Doctor of Medical Sciences, Professor, Chief Dermatovenereologist and Cosmetologist of the Health Committee of the Government of St. Direct comparative studies have shown that Guselkumab ® outperforms current standards in the treatment of psoriasis and demonstrates high efficacy in completely and almost completely clearing the skin of psoriatic manifestations 1,2,4,16 . In addition, the use of guselcumab is not associated with the risk of oncological and cardiovascular diseases, severe opportunistic infections, as well as the reactivation of tuberculosis and the development of inflammatory bowel diseases 1 . “The most important indicator of the effectiveness of treatment is the long-term preservation of the effect achieved and the long-term retention of patients on therapy,” the expert believes – According to the study, four years after the start of treatment, the largest proportion of patients remain on guselkumab therapy compared to drugs of previous generations. Cost of an annual course of treatment with Tremfya ® lower or comparable to the cost of therapy with other modern GIBP 27 . According to information for 2018, in Russia, the prevalence of psoriasis among the entire population was 242.4, the incidence was 66.5 per 100,000 population 28 . Between 2011 and 2018, the increase in the prevalence of psoriasis was 11% 6 . # # # About Guselcumab 0008 ® has been approved by the European Medicines Agency based on data from three phase III clinical trials 29 . The NAVIGATE study included patients who did not achieve clear or near clear skin [IGA score of 0 or 1] by week 16 of treatment with Stelara ® (ustekinumab), and who were then switched to either guselcumab therapy or remained on ustekinumab 4 therapy. Among patients switched to guselkumab, the proportion of patients who achieved clear or near clear skin (IGA 0/1) or achieved at least a 2-point improvement in IGA score between weeks 28 and 40 (relative to week 16) was statistically significantly higher compared to the ustekinumab group (1. In a head-to-head comparison study of the efficacy of guselcumab and secukinumab, the proportion of patients who achieved PASI 90 at 48 weeks of therapy was higher in the guselcumab group compared to patients treated with secukinumab (84% and 70%, respectively, p < 0.0001) 30 9001 0 . Guselcumab’s clinical trial program for psoriasis showed no trend towards increased risk of malignancy, cardiovascular disease, or serious infections, including TB and reactivation of latent TB with the drug 2, 3 , 4 .
About Janssen, Johnson & Johnson Pharmaceutical Companies At Janssen, we are creating a future where disease is a thing of the past. We are the Pharmaceutical Companies of Johnson & Johnson and we are working hard to make this future a reality for patients around the world. We defeat diseases with advanced science. We work in areas of medicine where we can make the most difference: cardiovascular disease, immune-mediated and metabolic diseases, infectious diseases and vaccines, diseases of the central nervous system, oncology, pulmonary arterial hypertension. Find out more at janssen.com. Follow: twitter.com/JanssenGlobal. 1. Griffiths et al. Poster Presentation Coastal Dermatology Symposium. 2020, October 15-16 th . 2. Blauvelt A. et al. J Am Acad Dermatol 2017;76:405-417. 3. Langley R. G. et al. Br J Dermatol 2018;178:114−123. 4. Reich, Kristianet al The Lancet. 10.1016/S0140-6736(19)31773-8. 5. Kerdel F. The Importance of Early Treatment in Psoriasis and Management of Disease Progression. J Drugs Dermatol . 2018;17(7):737–742. 6. National Institute of Arthritis and Musculoskeletal and Skin Disorders. 7. US Food and Drug Administration. 2016. Available at: https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM529856.pdf. Accessed January 2021. 8. State Register of Medicines [Electronic resource]. Available at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=06e7fa3a-e993-4bad-aa90-f28b2de029d3&t= The link is active as of 02/03/2021. 9. Reich K. et al. Presented at EADV 2017. Poster P1796. 10. Munir F. et al. Occup Med 2008; 58: 310–311 2. Blauvelt A, et al . J Am Acad Dermatol 2017;76:405−417 11. Griffiths C.E.M. et al. Presented at EADV 2017, Geneva, Switzerland 12. Griffiths C.E.M. et al. J Drugs Dermatol 2018;17:826–832 13. Griffiths C.E.M. et al. Presented at Fall Clinical Dermatology. Las Vegas: United States of America; 2018. 14. Reich K. et al. J Am Acad Dermatol 2017;76:418-431. 15. Langley R. G. et al . Br J Dermatol 2018;178:114–123. 16. Blauvelt A., Papp K. A. et al. J Am Acad Dermatol 2017;76(3):405–417. 17. Reich K and Armstrong A.W et al. J Am Acad Dermatol 2017;76(3):418–431. 18. Puig L. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert Rev Clin Immunol . 2019;15(6):589–597. 19. Fernández-Armenteros J. M. et al. J EurAcadDermatolVenereol. June 28, 2018. DOI: 10.1111/jdv.15159. 20. Mehta N. et al. Am J Med. 2011;124:775e1–6. 21. Ahlehoff O. et al. Eur Heart J. 2012;33:2054–64. 22. Augustin M, et al. EADV 2020 P1299 23. Warren RB, Smith CH, Yiu ZZN J Invest Dermatol. 2015;135(11):2632–2640 24. Egeberg A, Bryld LE, Skov L. J Am Acad Dermatol. 2019;81(1):173–178 25. Griffiths C.E.M., et al. Fall Clinical Dermatology Conference; October 17-20, 2019 0003 State Register of Maximum Selling Prices. 28. Kubanov A. A., Bogdanova E. V. Organization and results of medical care in the field of “dermatovenereology” in the Russian Federation. Results of 2018. Journal of Dermatology and Venereology . 2019;95(4):8–23. 29. The European Medicines Agency (EMA). [Electronic resource] Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tremfya-ii-17_en.pdf. Accessed: 02/03/2021. 30. Reich K., Armstrong A. W., Langley R. G. et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomized controlled trial. Lancet . 2019;394(10201):831–839. 394. DOI: 10.1016/S0140-6736(19)31773-8. |
Guselcumab therapy consists of two initiating injections at weeks 0 and 4 followed by maintenance injections once every 8 weeks 1 .
Petersburg, Chief Dermatovenereologist and Cosmetologist of the Northwestern Federal District, Head of the Department of Dermatovenereology, North-Western State Medical University named after I. I. Mechnikov.
At the same time, during this time, the vast majority (84%) 22,23,24,25 patients receiving Guselcumab® maintain the achieved response, characterized by the absence of disease recurrence. It is also important to note that Guselcumab® is characterized by a favorable safety profile, which makes it possible to use it for patients with cardiovascular diseases, IBD, multiple sclerosis and latent tuberculosis, in contrast to a number of drugs of other classes 1, 26
The VOYAGE 1 and 2 trials comparing Guselkumab ® with placebo and Adalimumab ® showed a high level of skin clearing after just 16 weeks of therapy with a 90% reduction in the Psoria Prevalence and Severity Index value for (PASI 90) in 73.3% and 70.0% of patients treated with Guselcumab ® (p < 0.001 versus placebo) 2.3 . By week 24 of therapy, PASI 90 was achieved in 80.2% and 75.2% of patients treated with Guselcumab ® , compared with 49.7% and 46.8% of patients treated with Adalimumab ® 900 11 respectively (P < 0.001) 2.3 .
5 vs. 0.7; P < 0.001) 4 .
Inventing how to help those who need help. We heal hopelessness with human warmth.
NIH Medline Plus. 2003;12(1):20–21.
Electronic resource: https://grls.rosminzdrav.ru/pricelims.aspx Access date 25.01.21 ISSN 2305-2066 (Print)
ISSN 2658-5049 (Online)
Tremfya (guselcumab) for the treatment of moderate and severe plaque psoriasis was included in the lists of Vital and Essential Drugs and ONLS
Home >
News >
Tremfya (guselcumab) for the treatment of moderate and severe plaque psoriasis was included in the lists of vital and essential drugs and ONLS
This is the first biologic that selectively blocks interleukin (IL)-23, a key cytokine in the immune system’s inflammatory response in psoriasis. According to information for 2018, in Russia, the prevalence of psoriasis among the entire population was 242.4, the incidence was 66.5 per 100 thousand population [1]. Between 2011 and 2018, the increase in the prevalence of psoriasis was 11%. About Guselcumab Links
|
Guselcumab therapy consists of two initiating injections at weeks 0 and 4 followed by maintenance injections once every 8 weeks. 
Now that the drug has been recommended by the commission of the Ministry of Health of the Russian Federation for inclusion in the lists of vital and essential drugs and ONLS, patients can count on a broad provision of effective treatment, the therapeutic response to which persists for a long time, ”comments Nikolai Nikolaevich Potekaev, chief freelance specialist in dermatovenereology and cosmetology of the Ministry of Health of Russia, director of the Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology of the Moscow Health Department, head of the department skin diseases and cosmetology N.I. Pirogov of the Ministry of Health of Russia”, Doctor of Medical Sciences, Professor.
3% and 70.0% of patients treated with guselcumab (compared to placebo). By week 24 of therapy, PASI 90 was observed in 80.2% and 75.2% of patients treated with guselkumab compared with 49.7% and 46.8% of patients treated with adalimumab, respectively. The stable result of therapy with guselcumab persists for a long time: after 3 years, 97.4% of patients have a response according to the PASI 75 index (significant skin cleansing) [5]. 
7). 